All Articles

Once patients are diagnosed with cancer, they begin their journey by forming new relationships with a multidisciplinary healthcare team that will support them during various points along the way. The definition of the patient journey has been broadened to answer important questions on how patients enter the healthcare system. Read More ›

A survey of patients with lung cancer conducted as COVID-19 pandemic shelter-in-place lockdowns were first easing in June 2020 in the United States revealed substantial anxieties about vulnerability to severe illness and access to care. Read More ›

The COVID-19 pandemic has had a profound impact on healthcare, especially in the management of patients with cancer, who are often not seeking healthcare in the same way as before the pandemic. At the 2021 International Association for the Study of Lung Cancer (IASLC) meeting, experts discussed the implications for patients with lung cancer, specifically. Read More ›

A small-molecule CD73 inhibitor (AB680) induced a 41% overall response rate (ORR) when combined with chemotherapy (with nab-paclitaxel and gemcitabine), plus the novel PD-1 inhibitor zimberelimab, as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma, according to results of the dose-escalation portion of a phase 1/1b study known as ARC-8. The data were presented as a poster at the 2021 ASCO Gastrointestinal Cancers Symposium. Read More ›

Bemarituzumab, an investigational first-in-class humanized immunoglobulin G1 monoclonal antibody that selectively binds to FGFR2b, improved progression-free survival (PFS) and overall survival (OS) when added to modified FOLFOX6 (mFOLFOX6) chemotherapy in patients with FGFR2b-positive advanced gastric or gastroesophageal junction (GEJ) cancer in the phase 2 FIGHT clinical trial. Read More ›

Genomic analysis of lung cancer in women who have never smoked may reveal novel mutations and structural alterations. Such an analysis, said Sitapriya Moorthi, PhD, Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, may suggest unique opportunities for future target identification and therapeutic intervention. Dr Moorthi discussed the results of a mutational analysis of the Women’s Health Initiative Cohort that were presented at the 2021 International Association for the Study of Lung Cancer meeting. Read More ›

Sexual orientation and assigned sex at birth are significant determinants in the utilization of lung cancer screening, according to an analysis from the Behavioral Risk Factor Surveillance System (BRFSS) 2018, a cross-sectional, nationally representative database, that looked at screening among lesbian, gay, bisexual, transgender (LGBT) populations. Read More ›

For patients with relapsed malignant mesothelioma, nivolumab (Opdivo) monotherapy is an effective treatment option, according to preliminary results of the phase 3 CONFIRM study, presented at the 2021 International Association for the Study of Lung Cancer meeting. Read More ›

We are pleased to present this 2021 Oncology Drug Coding and Updates special feature, designed to provide you with helpful information on the topic of oncology drug coding and important details on some of the drugs now available to treat patients with cancer. The COVID-19 pandemic led to many changes in patient care and treatment choices for oncology practices. Flexibility and innovation regarding both oral and infused/injected drugs became key to ensuring patient access to necessary treatments. Read More ›

The following tables of frequently used oncology drugs are intended to assist practice managers, other healthcare providers, and payers in the proper use of coding and billing information associated with the treatment of their patients. Read More ›